Characteristics of Acute Respiratory Failure in Patients with Type 1 Hepatorenal Syndrome (HRS-1) Treated with Terlipressin and Albumin in an Adult General ICU in the UK

被引：0
|
作者：
Cranshaw, J. H. [1 ]
Wilkins, P. L. [1 ]
机构：
[1] Royal Bournemouth Hosp, Bournemouth, Dorset, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2022年 / 205卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2904
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Initial Report of a Large, Randomized, Double Blind, Placebo-controlled, Phase 3 Trial of Terlipressin plus Albumin for the Treatment of Type 1Hepatorenal Syndrome (HRS-1): The REVERSE Study
    Boyer, Thomas D.
    Sanyal, Arun J.
    Wong, Florence
    Frederick, R. Todd
    Lake, John R.
    O'Leary, Jacqueline G.
    Ganger, Daniel
    Box, Terry D.
    Jamil, Khurram
    Pappas, Stephen Chris
    HEPATOLOGY, 2014, 60 : 255A - 255A
  • [22] Terlipressin and albumin in cirrhotic patients with hepatorenal syndrome type-1 with and without active infection
    Serrano-Romero, M.
    Pascasio, J. M.
    Sousa, J. M.
    Cayuela, A.
    Ferrer, M. T.
    Gomez-Navarro, E.
    Prieto, J. L.
    Sayago, M.
    Cabanillas, M.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S123 - S124
  • [23] Terlipressin Use, Transplant Rate, and Post-Transplant Outcomes in Patients With Type 1 Hepatorenal Syndrome (HRS)
    Sigal, Samuel
    Jamil, Khurram
    Pappas, Stephen Chris
    Sanyal, Arun J.
    Huang, Singyue
    HEPATOLOGY, 2017, 66 : 946A - 946A
  • [24] EFFICACY OF MIDODRINE AND OCTREOTIDE (MIDO/OCTR) ON THE OUTCOME OF TYPE 1 HEPATORENAL SYNDROME (HRS-1) AT A UNIVERSITY TRANSPLANT CENTER
    Karim, Yasmin K.
    Liu, Eashen M.
    Lewis, James H.
    HEPATOLOGY, 2008, 48 (04) : 1068A - 1068A
  • [25] Vasoactive treatment of hepatorenal syndrome type 1 (HRS1) with midodrine, octreotide and albumin
    Schepke, M
    Malayeri, H
    Heller, J
    Sauerbruch, T
    GASTROENTEROLOGY, 2003, 124 (04) : A664 - A664
  • [26] Type 1 hepatorenal syndrome in cirrhosis.: Predictive factors for survival in patients treated with terlipressin
    Durand, F
    Colle, I
    Pessione, E
    Bernuau, J
    Barrière, E
    Lebrec, D
    Valla, DC
    Moreau, R
    JOURNAL OF HEPATOLOGY, 2000, 32 : 63 - 63
  • [27] TERLIPRESSIN GIVEN AS CONTINUOUS INTRAVENOUS INFUSION VERSUS TERLIPRESSIN GIVEN AS INTRAVENOUS BOLUSES IN THE TREATMENT OF TYPE 1 HEPATORENAL SYNDROME (HRS) IN PATIENTS WITH CIRRHOSIS
    Angeli, P.
    Fasolato, S.
    Cavallin, M.
    Trotta, E.
    Maresio, G.
    Callegaro, A.
    Galioto, A.
    Mazza, E.
    Sticca, A.
    Benetti, G.
    Gatta, A.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S73 - S73
  • [28] Treatment Response to Terlipressin Plus Albumin Varies by Precipitating Factor in Patients With Hepatorenal Syndrome Type 1
    Frederick, Richard T.
    Lim, Nicholas
    Khan, Mohammad
    Zafar, Zunaira
    Jamil, Khurram
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S865 - S866
  • [29] TERLIPRESSIN, IN COMBINATION WITH ALBUMIN, IS AN EFFECTIVE THERAPY FOR HEPATORENAL SYNDROME TYPE 1 IN PATIENTS AGED ≥65 YEARS
    Mujtaba, Muhammad
    Gamilla-Crudo, Ann Kathleen
    Merwat, Shehzad
    Hussain, Syed
    Karim, Aftab
    Jamil, Khurram
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (04) : S15 - S15
  • [30] Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure (vol 56, pg 1284, 2022)
    Wong, F.
    Pappas, S. C.
    Reddy, K. R.
    Vargas, H.
    Curry, M. P.
    Sanyal, A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (03) : 429 - 429
12345